Document is current
Any future updates will be listed below
-
Authors
Unterrainer, Lena M.
Schmid, Hans P. https://orcid.org/0009-0002-1259-358X
Kunte, Sophie C.
Holzgreve, Adrien
Toms, Johannes
Menold, Paula
Cyran, Clemens C.
Karl, Alexander
Tschirdewahn, Stephan
Ledderose, Stephan T.
Eismann, Lennert
Tamalunas, Alexander J.
Scheifele, Maximilian
Stief, Christian G.
Unterrainer, Marcus
Casuscelli, Jozefina
Schulz, Gerald B.
-
Funding
Funding for this research was provided by:
Ludwig-Maximilians-Universität München
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 18 March 2025
First Online: 24 April 2025
Declarations
:
: Our study was approved by the “LMU Ethikkommission der Medizinischen Fakultät” (Ethics Committee of the LMU Munich, Medical faculty, # 24–0255) in accordance with the guidelines of the Declaration of Helsinki and its subsequent amendments.
: All authors declare that informed consent for PET/CT imaging prior to the examination was obtained from all individual participants included in the study.
: The precursors for both used radiotracers were provided by SOFIE (21000 Atlantic Blvd., Ste 730, Dulles, VA 20166).
: Clinical trial number: not applicable.
: The authors have no relevant financial or non-financial interests to disclose.
: Lena M. Unterrainer reports funding from Bayerisches Zentrum für Krebsforschung (BZKF) and from the Munich Clinician Scientist Program (MCSP). She reports fees from Novartis (speaker), Telix (consultant) and Astellas Pharma Inc. (speaker) outside of the submitted work. Johannes Toms reports funding from the Friedrich-Baur-Stiftung, which was used to establish the radiosynthesis of [18F]F-FAPI- 74 for clinical use. Stephan T. Ledderose reports funding from Bayerisches Zentrum für Krebsforschung (BZKF).
